Michael J. Yang
Insider
First SEC filing: June 12, 2026 · Latest: June 12, 2026
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net: $0
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| July 1, 2026 | IONS | A | 2,301 | · | · | 9,451 Direct | +32.18% | Acquired | (price as of 2026-10-02) |
| July 1, 2026 | IONS | A | 5,369 | · | · | 5,369 Direct | · | Acquired | (price as of 2026-10-02) |
| June 10, 2026 | PCRX | A | 10,891 | · | · | 10,891 Direct | · | Acquired | (price as of 2026-10-02) |
| June 10, 2026 | PCRX | A | 6,405 | · | · | 19,798 Direct | +47.82% | Acquired | (price as of 2026-10-02) |
| Jan. 15, 2026 | IONS | M | 1,930 | · | · | 7,150 Direct | -21.26% | Disposed | (price as of 2026-10-02) |
| Jan. 15, 2026 | IONS | M | 1,930 | · | · | 7,940 Direct | +32.11% | Acquired | (price as of 2026-10-02) |
| July 15, 2025 | IONS | M | 4,079 | · | · | 9,080 Direct | -31.00% | Disposed | (price as of 2026-10-02) |
| July 15, 2025 | IONS | M | 4,079 | · | · | 6,010 Direct | +211.24% | Acquired | (price as of 2026-10-02) |
| July 1, 2025 | IONS | A | 5,220 | · | · | 13,159 Direct | +65.75% | Acquired | (price as of 2026-10-02) |
| July 1, 2025 | IONS | A | 11,518 | · | · | 11,518 Direct | · | Acquired | (price as of 2026-10-02) |
| June 11, 2025 | PCRX | A | 6,163 | · | · | 13,393 Direct | +85.24% | Acquired | (price as of 2026-10-02) |
| June 11, 2025 | PCRX | A | 11,279 | · | · | 11,279 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 15, 2025 | IONS | M | 1,931 | · | · | 7,939 Direct | -19.56% | Disposed | (price as of 2026-10-02) |
| Jan. 15, 2025 | IONS | M | 1,931 | · | · | 1,931 Direct | · | Acquired | (price as of 2026-10-02) |
| Aug. 14, 2024 | PCRX | P | 2,000 | $12.90 | $25,800 | 7,230 Direct | +38.24% | Acquired | 95.4% (price as of 2026-10-02) |
| July 1, 2024 | IONS | A | 4,079 | · | · | 9,870 Direct | +70.44% | Acquired | (price as of 2026-10-02) |
| July 1, 2024 | IONS | A | 10,111 | · | · | 10,111 Direct | · | Acquired | (price as of 2026-10-02) |
| June 12, 2024 | PCRX | A | 5,230 | · | · | 5,230 Direct | · | Acquired | (price as of 2026-10-02) |
| June 12, 2024 | PCRX | A | 12,179 | · | · | 12,179 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 15, 2024 | IONS | A | 5,791 | · | · | 5,791 Direct | · | Acquired | (price as of 2026-10-02) |
| Dec. 14, 2023 | IONS | A | 12,356 | · | · | 12,356 Direct | · | Acquired | (price as of 2026-10-02) |
| Oct. 6, 2023 | PCRX | A | 30,967 | · | · | 30,967 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 6, 2021 | ACAD | M | 2,722 | · | · | 8,167 Direct | -25.00% | Disposed | (price as of 2026-10-02) |
| Jan. 6, 2021 | ACAD | S | 1,120 | $53.34 | $59,741 | 8,059 Direct | -12.20% | Disposed | -62.6% (price as of 2026-10-02) |
| Jan. 6, 2021 | ACAD | M | 2,722 | · | · | 9,179 Direct | +42.16% | Acquired | (price as of 2026-10-02) |
| Oct. 16, 2020 | ACAD | S | 1,247 | $42.56 | $53,072 | 6,457 Direct | -16.19% | Disposed | -53.1% (price as of 2026-10-02) |
| Oct. 15, 2020 | ACAD | M | 2,500 | · | · | 5,000 Direct | -33.33% | Disposed | (price as of 2026-10-02) |
| Oct. 15, 2020 | ACAD | M | 2,500 | · | · | 7,704 Direct | +48.04% | Acquired | (price as of 2026-10-02) |
| July 7, 2020 | ACAD | M | 14,750 | · | · | 44,292 Direct | -24.98% | Disposed | (price as of 2026-10-02) |
| July 7, 2020 | ACAD | M | 5,000 | · | · | 25,000 Direct | -16.67% | Disposed | (price as of 2026-10-02) |
| July 7, 2020 | ACAD | M | 7,500 | · | · | 570,000 Direct | -1.30% | Disposed | (price as of 2026-10-02) |
| July 7, 2020 | ACAD | S 10b5-1 | 11,100 | $56.54 | $627,594 | 5,204 Direct | -68.08% | Disposed | -64.7% (price as of 2026-10-02) |
| July 7, 2020 | ACAD | S 10b5-1 | 16,150 | $56.05 | $905,208 | 16,304 Direct | -49.76% | Disposed | -64.4% (price as of 2026-10-02) |
| July 7, 2020 | ACAD | M | 14,750 | $25.12 | $370,520 | 32,454 Direct | +83.31% | Acquired | -20.6% (price as of 2026-10-02) |
| July 7, 2020 | ACAD | M | 5,000 | $21.28 | $106,400 | 17,704 Direct | +39.36% | Acquired | -6.3% (price as of 2026-10-02) |
| July 7, 2020 | ACAD | M | 7,500 | $19.98 | $149,850 | 12,704 Direct | +144.12% | Acquired | -0.2% (price as of 2026-10-02) |
| April 30, 2020 | ACAD | S | 1,501 | $49.21 | $73,864 | 5,204 Direct | -22.39% | Disposed | -59.5% (price as of 2026-10-02) |
| April 29, 2020 | ACAD | M | 4,206 | · | · | 12,621 Direct | -25.00% | Disposed | (price as of 2026-10-02) |
| April 29, 2020 | ACAD | M | 4,206 | · | · | 6,705 Direct | +168.31% | Acquired | (price as of 2026-10-02) |
| Jan. 6, 2020 | ACAD | A | 10,889 | · | · | 10,889 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 6, 2020 | ACAD | A | 39,516 | · | · | 39,516 Direct | · | Acquired | (price as of 2026-10-02) |
| Dec. 12, 2019 | ACAD | M | 72,979 | · | · | 312,500 Direct | -18.93% | Disposed | (price as of 2026-10-02) |
| Dec. 12, 2019 | ACAD | M | 10,000 | · | · | 30,000 Direct | -25.00% | Disposed | (price as of 2026-10-02) |
| Dec. 12, 2019 | ACAD | M | 22,500 | · | · | 577,500 Direct | -3.75% | Disposed | (price as of 2026-10-02) |
| Dec. 12, 2019 | ACAD | S 10b5-1 | 5,032 | $43.74 | $220,100 | 2,499 Direct | -66.82% | Disposed | -54.4% (price as of 2026-10-02) |
| Dec. 12, 2019 | ACAD | S 10b5-1 | 100,447 | $44.49 | $4,468,887 | 7,531 Direct | -93.03% | Disposed | -55.2% (price as of 2026-10-02) |
| Dec. 12, 2019 | ACAD | M | 72,979 | $35.86 | $2,617,027 | 107,978 Direct | +208.52% | Acquired | -44.4% (price as of 2026-10-02) |
| Dec. 12, 2019 | ACAD | M | 10,000 | $21.28 | $212,800 | 34,999 Direct | +40.00% | Acquired | -6.3% (price as of 2026-10-02) |
| Dec. 12, 2019 | ACAD | M | 22,500 | $19.98 | $449,550 | 24,999 Direct | +900.36% | Acquired | -0.2% (price as of 2026-10-02) |
| Dec. 9, 2019 | ACAD | M | 14,521 | · | · | 385,479 Direct | -3.63% | Disposed | (price as of 2026-10-02) |
| Dec. 9, 2019 | ACAD | S 10b5-1 | 3,502 | $50.05 | $175,275 | 1,623 Direct | -68.33% | Disposed | -60.1% (price as of 2026-10-02) |
| Dec. 9, 2019 | ACAD | S 10b5-1 | 11,019 | $50.60 | $557,561 | 5,125 Direct | -68.25% | Disposed | -60.6% (price as of 2026-10-02) |
| Dec. 9, 2019 | ACAD | M | 14,521 | $35.86 | $520,723 | 16,144 Direct | +894.70% | Acquired | -44.4% (price as of 2026-10-02) |
| Oct. 15, 2019 | ACAD | M | 2,500 | · | · | 7,500 Direct | -25.00% | Disposed | (price as of 2026-10-02) |
| Oct. 15, 2019 | ACAD | S | 877 | $39.65 | $34,773 | 1,623 Direct | -35.08% | Disposed | -49.7% (price as of 2026-10-02) |
| Oct. 15, 2019 | ACAD | M | 2,500 | · | · | 2,500 Direct | · | Acquired | (price as of 2026-10-02) |
| April 29, 2019 | ACAD | A | 16,827 | · | · | 16,827 Direct | · | Acquired | (price as of 2026-10-02) |
| April 29, 2019 | ACAD | A | 59,042 | · | · | 59,042 Direct | · | Acquired | (price as of 2026-10-02) |
| Oct. 15, 2018 | ACAD | A | 10,000 | · | · | 10,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Oct. 15, 2018 | ACAD | A | 40,000 | · | · | 40,000 Direct | · | Acquired | (price as of 2026-10-02) |
| April 18, 2018 | ACAD | A | 60,000 | · | · | 60,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Sept. 7, 2017 | ACAD | A | 93,750 | · | · | 93,750 Direct | · | Acquired | (price as of 2026-10-02) |
| March 29, 2017 | ACAD | A | 400,000 | · | · | 400,000 Direct | · | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| July 1, 2026 | IONS | Restricted Stock Unit | Common Stock | · | · | 2,301 | Acquired |
| July 1, 2026 | IONS | Non-Qualified Stock Option (right to buy) | Common Stock | $79.19 | June 30, 2036 | 5,369 | Acquired |
| June 10, 2026 | PCRX | Stock Option (Right to Buy) | Common Stock | $23.42 | June 10, 2036 | 10,891 | Acquired |
| Jan. 15, 2026 | IONS | Restricted Stock Unit | Common Stock | · | · | 1,930 | Disposed |
| July 15, 2025 | IONS | Restricted Stock Unit | Common Stock | · | · | 4,079 | Disposed |
| July 1, 2025 | IONS | Restricted Stock Unit | Common Stock | · | · | 5,220 | Acquired |
| July 1, 2025 | IONS | Non-Qualified Stock Option (right to buy) | Common Stock | $39.94 | June 30, 2035 | 11,518 | Acquired |
| June 11, 2025 | PCRX | Stock Option (Right to Buy) | Common Stock | $24.34 | June 11, 2035 | 11,279 | Acquired |
| Jan. 15, 2025 | IONS | Restricted Stock Unit | Common Stock | · | · | 1,931 | Disposed |
| July 1, 2024 | IONS | Restricted Stock Unit | Common Stock | · | · | 4,079 | Acquired |
| July 1, 2024 | IONS | Non-Qualified Stock Option (right to buy) | Common Stock | $47.11 | June 30, 2034 | 10,111 | Acquired |
| June 12, 2024 | PCRX | Stock Option (Right to Buy) | Common Stock | $28.68 | June 12, 2034 | 12,179 | Acquired |
| Jan. 15, 2024 | IONS | Restricted Stock Unit | Common Stock | · | · | 5,791 | Acquired |
| Dec. 14, 2023 | IONS | Non-Qualified Stock Option (right to buy) | Common Stock | $49.82 | Dec. 14, 2033 | 12,356 | Acquired |
| Oct. 6, 2023 | PCRX | Stock Option (Right to Buy) | Common Stock | $29.80 | Oct. 6, 2033 | 30,967 | Acquired |
| Jan. 6, 2021 | ACAD | Restricted Stock Units | Common Stock | · | · | 2,722 | Disposed |
| Oct. 15, 2020 | ACAD | Restricted Stock Units | Common Stock | · | · | 2,500 | Disposed |
| July 7, 2020 | ACAD | Stock Option (Right to Buy) | Common Stock | $25.12 | April 29, 2029 | 14,750 | Disposed |
| July 7, 2020 | ACAD | Stock Option (Right to Buy) | Common Stock | $21.28 | Oct. 14, 2028 | 5,000 | Disposed |
| July 7, 2020 | ACAD | Stock Option (Right to Buy) | Common Stock | $19.98 | April 17, 2028 | 7,500 | Disposed |
| April 29, 2020 | ACAD | Restricted Stock Units | Common Stock | · | · | 4,206 | Disposed |
| Jan. 6, 2020 | ACAD | Restricted Stock Units | Common Stock | · | · | 10,889 | Acquired |
| Jan. 6, 2020 | ACAD | Stock Options (Right to Buy) | Common Stock | $42.81 | Jan. 6, 2030 | 39,516 | Acquired |
| Dec. 12, 2019 | ACAD | Stock Option (Right to Buy) | Common Stock | $35.86 | March 28, 2027 | 72,979 | Disposed |
| Dec. 12, 2019 | ACAD | Stock Option (Right to Buy) | Common Stock | $21.28 | Oct. 14, 2028 | 10,000 | Disposed |
| Dec. 12, 2019 | ACAD | Stock Option (Right to Buy) | Common Stock | $19.98 | April 17, 2028 | 22,500 | Disposed |
| Dec. 9, 2019 | ACAD | Stock Option (Right to Buy) | Common Stock | $35.86 | March 28, 2027 | 14,521 | Disposed |
| Oct. 15, 2019 | ACAD | Restricted Stock Units | Common Stock | · | · | 2,500 | Disposed |
| April 29, 2019 | ACAD | Restricted Stock Units | Common Stock | · | · | 16,827 | Acquired |
| April 29, 2019 | ACAD | Stock Options (Right to Buy) | Common Stock | $25.12 | April 29, 2029 | 59,042 | Acquired |
| Oct. 15, 2018 | ACAD | Restricted Stock Units | Common Stock | · | · | 10,000 | Acquired |
| Oct. 15, 2018 | ACAD | Stock Option (right to buy) | Common Stock | $21.28 | Oct. 15, 2028 | 40,000 | Acquired |
| April 18, 2018 | ACAD | Stock Option (right to buy) | Common Stock | $19.98 | April 17, 2028 | 60,000 | Acquired |
| Sept. 7, 2017 | ACAD | Stock Option (right to buy) | Common Stock | $35.80 | Sept. 6, 2027 | 93,750 | Acquired |
| March 29, 2017 | ACAD | Stock Option (right to buy) | Common Stock | $35.86 | March 28, 2027 | 400,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2020 | $516,805 | · | $932,316 | $935,316 | $210,921 | · | $25,321 | $2,620,679 |
| 2019 | $500,701 | · | $1,291,323 | $842,087 | $287,328 | · | $22,383 | $2,943,821 |
| 2018 | $485,250 | · | $212,800 | $2,077,607 | $237,773 | · | $169,480 | $3,182,910 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.